Felicia Pagliuca
Fondateur chez Semma Therapeutics, Inc.
Profil
Felicia Pagliuca is the founder and has held the title of Vice President-Cell Biology Research & Development at Semma Therapeutics, Inc. since 2015.
She received an undergraduate degree from Duke University and a doctorate degree from the University of Cambridge.
Postes actifs de Felicia Pagliuca
| Sociétés | Poste | Début |
|---|---|---|
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Fondateur | 01/01/2015 |
Formation de Felicia Pagliuca
| Duke University | Undergraduate Degree |
| University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |